Fancy stat!

I was taking a quick look at my blog status and a fancy stat figure brought in a smile in my face and could not resist sharing with the readers (without whom this wouldn't have become possible)

Thanks for visiting my blog & subscribing for feeds. Will continue to feed you with useful news & analysis.

Good bye 2011 & Welcome 2012

A look at the journey of this blog.

482 posts since the inception in May 2009

About 18000 visitors in around 2.5 years.

More than half of the visitors are from outside of India

Look at the graphics below

Thanks for all your support and regular visits. I will continue to post useful info and improvise on the content.

Happy New Year to all!

Blogs will resume on Jan 1, 2012

Total number of registered pharmacists in Karnataka

The total number of registered pharmacists in Karnataka as on 16th June 2010 is 43652.

By 2010, India will have maximum no. of diabetics

The global projections by International Diabetes Federation (IDF) also show that India has a much lesser prevalence of the disease than most other countries including US.

But that is just about the only satisfying bit of statistics unveiled in IDF's latest Diabetes Atlas. IDF, which tracks the global spread of this scourge, says that by next year, the country will be home to 50.8 million diabetics, making it the world's unchallenged diabetes capital. And the number is expected to go up to a whopping 87 million -- 8.4% of the country's adult population by 2030.
China stands second in this infamous table with 43.2 million diabetes cases at present, which is expected to increase to 62.6 million by 2030.

The disease will prove costly for India, both in terms of lives lost and money wasted. In India, it will kill around 10.07 lakh people in the age group of 20-79 years every year the majority being women (5.81 lakh) from 2010.

Diabetes will cost the world economy dear -- $376 billion in 2010, or 11.6% of total world healthcare expenditure. Though India will spend only 1% of the total diabetes spending worldwide, the amount itself is staggering -- $2.8 billion. US, on the other hand, will account for $198 billion or 52.7% of the total diabetes spending worldwide. By 2030, diabetes is expected to cost the world economy $490 billion.

According to the latest figures released on Tuesday night at Montreal, Pakistan, which now stands 7th in the "top 10 worst affected countries with diabetes" list with 7.1 million diabetics, will jump three places by 2030 to become the 4th worst affected with 13.8 million diabetics. Another of India's neighbours, Bangladesh, which at present does not figure in this list, will make an entry in another two decades, to claim the 7th worst affected country slot with 10.4 million diabetics.

Globally, the number of diabetes patients has risen sharply. While in 1985, 30 million people had diabetes, the number rose to 150 million in 2000. In 2010, 285 million people (6.6% of the global population in the age group 20-79) were found to be diabetic. However, by 2030, an estimated 435 million people are expected to suffer from this disease -- 7.8% of the adult population.

Record Number of Medicines In Development to Treat Diseases Affecting Women

America’s pharmaceutical research and biotechnology companies are working on nearly 1,000 life–changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

In the U.S., diseases that disproportionately affect women include diabetes, which has reached epidemic proportions and affects 11 million women nationwide. Autoimmune diseases strike women three times more and anxiety and depression two times more women than men. The number one killer of American women is heart disease.

The report lists 969 new medicines in development. They include 112 new treatments for breast cancer, 86 new treatments for obstetric/gynecologic conditions, 76 for asthma, 114 for autoimmune diseases, 155 for diabetes, 131 for arthritis, and 80 for Alzheimer’s disease.

One medicine in the report is a potential cutting–edge treatment that attacks the cause of Alzheimer’s disease rather than merely treating its symptoms. Currently, treatment options for Alzheimer’s disease are limited. This groundbreaking medicine holds the potential to slow the progression of the disease and could vastly improve quality of life for Alzheimer’s patients. Women account for 70 percent of Alzheimer’s deaths.

click here to read the report

Clinical Trial Outsourcing in India to Post Double Digit Growth by 2012

In the recent economic scenario, outsourcing business in life sciences, especially pharmaceuticals and biopharmaceutical business, has displayed an upward trend. This has been led by outsourcing of clinical trials which share a major part of drug development costs.

A research study “Booming Clinical Trials Market in India” conducted by RNCOS anticipates that clinical trial outsourced market in India is forecasted to grow at a CAGR of over 30% during 2010-2012 to around US$ 600 Million by 2012. With this anticipated growth, India will become one of highest growing clinical trial destinations in the world. An extensive research has been done on Indian clinical trial market in order to identify key trends across the market. The report highlights that all the major pharmaceutical/biotech players as well as major CROs are making India their base for conducting global clinical trials as finding patients, who can qualify for a clinical trial, is relatively much easier in India as compared to the Western countries.

Various other factors such as increasing prevalence of diseases and low cost of clinical trials are also promoting this market. We have observed that there is no dominance in terms of competitive landscape. There are more than 100 firms working in India in the clinical trial market, with Syngene and Quintiles right on top in terms of market share.

Apart from this, there are also some restraints, like weak IPR protection, lack of trained staff, etc., which are blocking the proper growth of the market. So, in order to ensure proper growth of the industry, these issues need to be addressed efficiently. Our study analyzes the key markets and segments of the concerned industry to project the future scenario of the industry. According to our industry experts, several steps need to be taken by the Indian government to ensure an easy approval system for promoting foreign investments. The report also studies various factors which are fuelling the growth of country’s clinical research market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM564.htm

About RNCOS: RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.

Visitor Stat for August 2009

Pharma market hit by monsoon shortfall, growth at 8.9% in July 09: ORG IMS

The value growth in Indian pharma retail market has decreased in the month of July to 8.9 per cent, as compared to a growth of 18.3 per cent in the pervious month, owing to the monsoon shortfall in most parts of the country, according to the monthly Indian Pharmaceutical Market (IPM) report of ORG IMS.

The top five companies - Cipla Ltd, Ranbaxy Laboratories, GlaxoSmithKline Pharma, Piramal Healthcare and Sun Pharmaceuticals - continues to hold their position intact. Mankind Pharmaceuticals has jumped one rank up to secure the eighth position in the top 10 companies.
Among the top marketed products, Novartis' painkiller Voveran maintains its top position in July '09 too as compared to the performance of the previous month.

ORG IMS reflections captured some major movers and shakers when it came to top 10 products. In the month of July'09, Voveran has maintained its top position as compared to the month Jun'09. Zifi, the antibacterial medicine from FDC Limited, has leaped five ranks and moved up to rank eight in July. Revital, the dietary food supplement from Ranbaxy Lab has gained two ranks and moved up to rank seven, whereas the antibiotic drugs - Taxim from Alkem Lab and Augmentin from GSK - have gained one rank each and moved up to rank six and nine respectively.

Other top gainers include, Azithral leaped five ranks and moved up to rank 17, Calpol and Storvas leaped three ranks and Aciloc jumped up six ranks to 14, 18 and 22 respectively. Sporidex has gained five ranks and moved up to rank 25, details the report.

July Visitor Stat

June stat